Cellectis (CLLS) Net Income (2015 - 2026)
Cellectis (CLLS) posted quarterly Net Income of -$17.8 million for Q1 2026, up 2.0% year-over-year from -$17.4 million in Q1 2025, and up 83.17% quarter-over-quarter from -$105.5 million in Q4 2025.
Analysis
Cellectis (CLLS) Net Income (2015 - 2026) Analysis & Trends
Cellectis' Net Income history runs 12 years deep, the most recent figure standing at -$17.8 million for Q1 2026.
- In Q1 2026, Net Income rose 2.0% year-over-year to -$17.8 million; the TTM figure through Mar 2026 stood at -$85.2 million (down 65.09% YoY), while the FY2023 annual figure was $8.4 million, up 154.69% from the prior year.
- Net Income for Q1 2026 stood at -$17.8 million, up from -$105.5 million in the prior quarter.
- The five-year high for Net Income was $59.8 million in Q2 2022, with the low at -$105.5 million in Q4 2025.
- The 5-year median for Net Income is -$4.7 million (2023), against an average of -$6.4 million.
- The sharpest annual moves came in 2022 and 2025: Net Income surged 265.42% in 2022, then slumped 156.49% in 2025.
- Cellectis' Net Income stood at -$2.9 million in 2022, then jumped by 557.93% to $13.1 million in 2023, then sank by 414.52% to -$41.1 million in 2024, then tumbled by 156.49% to -$105.5 million in 2025, then soared by 83.17% to -$17.8 million in 2026.
- Business Quant data shows CLLS's Net Income at -$17.8 million in Q1 2026, -$105.5 million in Q4 2025, and $22.4 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Cellectis | 321.90 Mn | 155.05 Mn | - | -21.82 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -21.82 Mn |
| Mar 31, 2026 | -17.77 Mn |
| Dec 31, 2025 | -3.42 Mn |
| Sep 30, 2025 | 22.41 Mn |
| Jun 30, 2025 | -23.74 Mn |
| Mar 31, 2025 | -18.13 Mn |
| Dec 31, 2024 | -37.78 Mn |
| Sep 30, 2024 | 2.86 Mn |
| Jun 30, 2024 | -25.31 Mn |
| Mar 31, 2024 | 11.39 Mn |
| Dec 31, 2023 | -118.06 Mn |
| Sep 30, 2023 | -546,000.00 |
| Jun 30, 2023 | 17.56 Mn |
| Mar 31, 2023 | -26.57 Mn |
| Dec 31, 2022 | -5.61 Mn |
| Sep 30, 2022 | -29.09 Mn |
| Jun 30, 2022 | -19.45 Mn |
| Mar 31, 2022 | -5.62 Mn |
| Dec 31, 2021 | 222.13 Mn |
| Sep 30, 2021 | -42.37 Mn |